Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
alt text

Download “Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct”


Risk-Based Quality Management (RBQM) will be the operational foundation of next-generation clinical research. RBQM mandates new ways of thinking and operating that will change the clinical development process, from the concept and design of clinical trials to the infrastructure and methodologies used to conduct them.

A broad constellation of regulatory guidance is in progress to inform sponsors as industry implements this far-reaching revolution. In a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.

alt text

Complete the form to download your white paper!

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio

By completing this form you agree Parexel may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.